MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 143 participants.

Also called NCT01847144

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose basic science
Phase
Phase 4
Enrolled
  • 143 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01847144
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01847144. Randomized; no masking; primary purpose basic science. Start 2013-04 (registry gives no type); primary completion 2015-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes
Acronym
Mastermind
Intervention (Drug)
Gliclazide 80mg OD
Intervention (Drug)
Sitagliptin 100mg OD
Lead sponsor
Royal Devon and Exeter NHS Foundation Trust (class: other)
Collaborator
University of Exeter (class: other)

Record details

Record id
cardio:ct-nct01847144
Content hash
c29e814c20d91c889bc0b6a4c4016ed7f2fc636851a2cc288e7c9ed96261a0cc